Get Started

EIKN

NASD Eikon Therapeutics, Inc.
Oct 30, 2026 · 8:43 PM ET LAST TRADE Market Closed

$5.40 ↑ +0.09 (+1.69%) Trading Up from the previous close of $5.31, and at the day’s high of $5.40

YTD change
-64.00%
vs 20-day SMA
-24.05%
vs 200-day SMA
N/A

Price ranges

Previous day
$5.28 $5.83
open $5.69 close $5.35
-$0.34 (-5.98%)
Today
$5.01 $5.40
open $5.27 now $5.40
+$0.13 (+2.47%)
Past week
$5.28 $8.24
from $8.24 now $5.40
-$2.84 (-34.47%)
Past month
$5.28 $8.48
from $7.41 now $5.40
-$2.01 (-27.13%)
This year
$5.01 $17.40
from $15.00 now $5.40
-$9.60 (-64.00%)

Price & Performance

-4.31 (-44.77%) / 6M

$4.67$7.74$10.82$13.89Apr 30Jul 31Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 69.0% away from all-time highs of $17.40
  • EIKN is down 64% since the beginning of the year
  • EIKN is down 64% over the past 12 months
  • EIKN is down 27% over the past 1 month
  • 25% of all EIKN investors are betting against EIKN

EIKN reads poor: the 12-month move is -64.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-1.63
Earnings momentum +4.0% Quarterly EPS growth
Quarterly change +4.0%

Valuation

P/E ratio N/A
Enterprise value $10.3M
Beta 1.19

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$531.6M
Debt$252.2K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $292.5M

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.